AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Vaccine researchers are working on understanding the relationship of CD8+ T lymphocytes in immunity against human cytomegalovirus in allogeneic stem-cell transplants.
"Human cytomegalovirus (CMV) is a ubiquitous herpesvirus that is an important complication of bone marrow and allogeneic stem-cell transplant (HSCT). CD8+ T lymphocytes have an important role in immunity against CMV, but correlation between antigen-specific subpopulations of these cells and protection are still unclear," according to S.F. Lacey and colleagues, City Hope National Medical Center, Duarte, California.
"Flow analysis with fluorescently conjugated human leukocyte antigen (HLA) class I tetramers (Tet) was used to investigate levels of CMV-specific CD8+ T lymphocytes in peripheral blood monocyte cells (PBMC) samples from HSCT donors and recipients and their ability to produce interferon (IFN)-gamma or stimulation with either CMV antigenic peptide or nonspecific mitogenic stimulation. Chromium release assays were used to evaluate ex vivo CMV-specific cytotoxicity associated with the PBMC samples," the researchers explained in a study published in the journal Transplantation.
They reported "use of Tet in conjunction with fluorescently conjugated anti-T-cell receptor (TCR) beta-chain variable (Vbeta) monoclonal antibodies indicated that the Vbeta repertoires associated with Tet+ cells seen in two HSCT recipients were similar to the Vbeta repertoires of the Tet+ cells in their HSCT donors."
"Significant ex vivo cytotoxicity against peptide-loaded targets was measured from ...
Source: HighBeam Research, CMV reactivation in stem cell recipients studied.(cytomegalovirus)